Hit ‘em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target
Alan S. Cross
Abstract
Infections with antimicrobial-resistant (AMR) bacteria pose an increasing threat to the ability to perform surgical procedures, organ transplantation, and treat cancer among many other medical conditions. There are few new antimicrobials in the development pipeline. Vaccines against AMR Gram-negative bacteria may reduce the use of antimicrobials and prevent bacterial transmission. This review traces the origins of lipopolysaccharide (LPS)-based vaccines against Gram-negative bacteria, the role of O polysaccharides and LPS core regions as potential vaccine targets, the development of new vaccine technologies, and their application to vaccines in current development.
Topics & Concepts
LipopolysaccharideBiologyGram-negative bacteriaAntimicrobialBacteriaMicrobiologySepsisTransmission (telecommunications)ImmunologyEscherichia coliGeneBiochemistryGeneticsEngineeringElectrical engineeringImmune responses and vaccinationsImmune Response and InflammationInfant Nutrition and Health